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a b s t r a c t
Various branded low molecular weight heparins (LMWHs) have been used for the treatment and pre-
vention of thrombotic for over 20 years. With the introduction of generic LMWHs and the recent events
involvingheparin contamination, a greatdeal of effort is beingexpended in investigatingwaysofmonitor-
ing and regulating this class of complex drugs. In this paper, we present the characterization of different
forms of LMWHs, as well as the comparison of 5 enoxaparin copies from different manufactures. The
data suggests that, while some of these drugs are structurally comparable, speciﬁc analytical methods aseywords:
iosimilar
ow molecular weight heparin
uclear magnetic resonance
ircular dichroism
canning UV
well as biological and pharmacological tests may be used to address their similarity, quality and poten-
tial interchangeability. The proposed approach may also be useful in comparing biosimilar and branded
LMWHs.
© 2011 Elsevier Ltd.  Open access under the Elsevier OA license.rincipal component analysis
. Introduction
Numerous pharmacological actions of heparin are associated
ith the treatment of thromboembolic diseases. Heparin plays a
ole in coagulation due to its interaction with blood soluble pro-
eins aswell as its interactionswith the blood vessel and associated
ells. Consequently, blood clot formation can be efﬁciently moder-
ted by heparin and its derivatives. Unfractionated heparin (UFH)
s mostly obtained from porcine and bovine mucosa and has been
idely used for the treatment andprevention of thrombotic events.
t consists ofmolecular chains of various lengths varying from2000
o 40,000Da (Nader, Lopes, Rocha, Santos, & Dietrich, 2004).
Low molecular weight heparins (LMWHs) are smaller chains
f UFH that are obtained by various chemical and enzymatic
epolymerization processes. Since they are produced from natu-
al heparins, they must share structural features with the parent
ompound, however, the depolymerization process used for their
roduction leads to unique structural features.
∗ Corresponding author. Tel.: +55 11 5579 3175; fax: +55 11 5573 6407.
E-mail address: hbnader.bioq@epm.br (H.B. Nader).
1 These authors contributed equally to the work.
144-8617 © 2011 Elsevier Ltd. 
oi:10.1016/j.carbpol.2011.04.021
Open access under the Elsevier OA license.The main advantages of LMWHs over UFH are improved
bioavailability and higher anti-factor Xa/anti-factor IIa activity
ratios, with decreased hemorrhagic risk during prolonged treat-
ments (Hoppensteadt, 2006). Lovenox (INN enoxaparin), which is
obtained by the -eliminative cleavage of the heparin benzyl ester
by alkaline treatment, is themostpopular productwith anongrow-
ing net global sales rising by over 20% in 2008 (Gray & Mulloy,
2009). Since Lovenox is no longer protected by US patents and with
the introduction of generic products in many countries, including
the United States, copies of enoxaparin and other branded LMWHs
made by differentmanufactures are being introduced into themar-
ket (Ofosu, 2011).
The introduction of biosimilar products may be beneﬁcial since
it could result in lower treatment costs.Despite this advantage, they
raisenewconcerns regarding thepresenceof inactive, uncharacter-
ized, less and/or more active moieties not found in the originator
products as well as contaminants (Harenberg et al., 2009). Thus,
speciﬁc guidelines for the approval of LMWH copies are necessary.
In the present paper, we have examined the chemical charac-
teristics of different LMWHs using a combination of spectroscopic
methods and multivariate analysis. This approach provides a
simpler and reliable method for establishing the similarity or dif-
ferences among LMWHs.
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190nm for DS, C4S and C6S may reﬂect their difference in glyco-04 M.A. Lima et al. / Carbohydr
. Materials and methods
.1. Heparin and low molecular weight heparins
Enoxaparins (∼100 IU/mg) were obtained from Sanoﬁ-aventis
armacêutica Ltda (Suzano, Brazil), Sanoﬁ-aventis (Bridgewa-
er, USA), Eurofarma Laboratórios Ltda (São Paulo, Brazil),
lausiegel Farmacêutica (Cotia, Brazil), Aspen Pharma (Rio
e Janeiro, Brazil) and Laboratório Cristália (Itapira, Brazil);
adroparins (∼110 IU/mg) were obtained from different manu-
actures; Gammaparin was obtained from Corcon Pharmaceutical,
ilan, Italy; Tinzaparin (∼90 IU/mg)wasobtained fromtheUSmar-
et andUFHs (∼180 IU/mg)were obtained fromGentiumSpA (Villa
uardia (CO), Italy) and Kim Master (Kim Master Produtos Quími-
os Ltd., Brazil). The glycosaminoglycans (GAGs) – chondroitin
-sulfate (C4S), chondroitin 6-sulfate (C6S) and dermatan sulfate
DS) – were purchased from Seikagaku Kojii Corporation (Tokyo,
apan). All of the tested agents were in their sodium form.
The enoxaparin copies used for this study received market
pproval in Brazil and possess anti-factor Xa and IIa activity of
00–110 IU/mg and 25–30 IU/mg, respectively.
.2. Nuclear magnetic resonance (NMR)
For NMR experiments, the samples were deuterium exchanged
y repeated dissolution in D2O and freeze-drying. Spectra were
btained from solutions in D2O at 30 ◦C, using TMSP as standard
ı=0). All spectra were obtained with a Bruker 400MHz AVANCE
II NMR spectrometer (Bruker Daltonics, Germany) with a 5mm
nverse gradient probe. 1D and 2D assignments were performed
sing 1H-(zg, andzgpr) andHSQC (hsqcetgpsi) programs.HSQCwas
cquired using 8–16 scans, respectively, per series of 2K×512W
ata points with zero ﬁlling in F1 (4K) prior to Fourier transforma-
ion (Viccini et al., 2009).
.3. Scanning UV spectroscopy
Scanning UV spectroscopy was performed on Perkin-Elmer
ambda 25 UV/VIS spectrometer (Turku, Finland). UV spectra were
ecorded at 1mg/mL in water from 190 to 320nm at a scanning
ate of 120nm/min with 1nm resolution at room temperature.
.4. Circular dichroism (CD)
CD spectrawere recorded on a J-810 spectropolarimeter (JASCO,
aston, MD), using a quartz sample cell of 0.1 cm path length,
etween 260 and 190nm at a scanning rate of 50nm/min with
.5nm resolution at 37 ◦C. The values are presented in Molar CD.
D spectra were recorded at 10mg/mL in water and are relative
o (+)-10-camphorsulfonic acid (1.0mg/mL). The resulting spectra
ere saved as ASC ﬁles for subsequent multivariate analysis.
.5. Multivariate analysis
Multivariate analysis was performed as previously described
Lima et al., 2011) using the software R: A Language and Envi-
onment for Statistical Computing (R Foundation for Statistical
omputing, Viena, Austria. http://cran.r-project.org/), with prior
ean centering.
. Results.1. Scanning UV of different LMWHs
The electronic transitions of the carboxylate groups of the
ronate residues and the N-acetyl chromophores of the hex-Fig. 1. Scanning UV spectra of different LMWHs. UFH, unfractionated heparin.
osamine residues (n→ * and  → * transitions) along the GAG
chain are the structural features responsible for the majority of the
UV spectral bands shown in Fig. 1.
The band around 190–200nm arises mainly from the carboxy-
late chromophore of iduronate and glucuronate as well as N-acetyl
chromophores of the hexosamine. For the LMWHs produced by -
eliminative methods, enoxaparins and tinzaparin, an extra band
from 215 to 255nm is observed due to the 4,5 double bond (C C)
present in the non-reducing uronic acid (U).
3.2. CD spectra of LMWHs and GAGs
CD spectra of LMWHs are shown in Fig. 2. The spectral features
represent differences in right and left hand circularly polarized
light arising from transitions occurring within the oxygen atoms
(ring, glycosidic linkage and hydroxyl), maxima around 200nm, as
well as electronic transition occurring within the carboxylate and
N-acetyl chromophores, negative band with its maxima around
210nm. Both chemical (enoxaparin) and enzymatic (tinzaparin)
-eliminative methods introduce a 4,5 double bond (C C) into
the uronate residue at the non-reducing end, generating a new
chromophore as evidenced by the negative band with its maxima
around 230nm. Interestingly, the CD spectra from LWMHs pro-
duced by nitrous acid degradation (nadroparin) and -radiation
(gammaparin) are comparable to the UFH one, suggesting that no
newchromophoreswere introduced into thesemolecules through-
out their depolymerization process.
It is well known that circular dichroism is sensitive to sugar
conformation, since their uronic acids (-d-Glucuronic acid and
-l-Iduronic acid) give rise to signals of opposite sign (Morris,
Rees, Sanderson, & Thom, 1975; Rudd et al., 2009). As shown in
Fig. 2, the CD spectra for DS, C4S and C6S–GAGs that contain
mainly glucuronic acid as their hexuronic acid – are quite pecu-
liar displaying only a broad negative band with its maxima around
210nm. DS has its negative band slightly shifted with its maxima
around 207nm, which may be explained by the fact that it also
contains iduronic acid. Also, the lack of the positive band aroundsidic linkage. The latter compounds are composed of N-acetylated
-d-galactosamine (-linkage), while in heparins the hexosamine
moiety is either N-acetylated or N-sulfated -d-glucosamine
(-linkage).
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Fig. 2. CD spectra of different LMWHs and natural occurring GAGs. (a) LMWHs and UFH. (b
C6S, chondroitin 6-sulfate; DS, dermatan sulfate. The vertical dashed lines highlight the d
Fig. 3. 1H NMR of UFH and different LMWHs. Major signals are identi-
ﬁed. UFH, unfractionated heparin; LMWHs, low molecular weight heparins;
ANS, 2-deoxy-2-sulfoamino-d-glucopyranose; I2S, 2-O-sulfo-iduronic acid; G,
glucuronic acid; A3S, 2-deoxy-3-O-sulfo-2-amino-d-glucopyranose; ANAc, 2-
deoxy-2-acetylamino-d-glucopyranose; 1,6-an.A, 2-amino-1,6-anhydro-2-deoxy-
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h-d-glucopyranose; AM.ol, 2,5-anhydromannitol; U2S, 2-O-sulfo-4-deoxy--l-
hreo-hex-4-enopyranosil uronic acid, NR, non-reducing end.
.3. 1H NMR of LMWHs
The major disaccharide repeating unit: -4)--l-IdoA2SO3--
1→4)-d-GlcNSO3,6SO3 (I2S-ANS,6S) present in UFHs corresponds
o the major signals on the LMWHs 1H NMR spectra (Fig. 3). Minor
ignals are due to under- and over-sulfated sequences and those
ssociated with the depolymerization process used in their pro-
uction.
Enoxaparin and tinzaparin, which are produced by chemi-
al and enzymatic eliminative reactions, respectively, possess
nsaturated 2-O-sulfated uronic acid (U2S) at the nonreducing
nd of their chains, which is rapidly noticed by a signal around
ppm (Fig. 3). Also, the signals around 5.8pmm and 3.2ppm,
orresponding to U and 2-sulfo-amino-1,6-anhydro-2-deoxy--
-glucopyranose (1,6-an.A), respectively, make the enoxaparin 1H
MR spectrum more distinct from heparin than the tinzaparin
ne as the enzymatic procedure used for the production of tinza-
arin does not yield these types ofmonosaccharides.Moreover, the
igher complexity on the enoxaparin spectrum is due to the multi-) natural occurring GAGs. UFH, unfractionated heparin; C4S, chondroitin 4-sulfate;
ifference on the negative maxima on DS, C4S and C6S spectra.
step reactions and side reactions that occur when its fragments are
generated during the alkaline treatment (Guerrini, Guglieri, Naggi,
Sasisekharan, & Torri, 2007).
The main difference on Nadroparin 1H NMR spectrum, which is
produced by a deamination process where heparin is nitrosylated
at the amino group of its N-sulfoglucosamine residues (Guerrini
et al., 2007), to the UFH spectrum is the signal around 5.2ppm. This
signal represents the 2,5-anhydromannitol (AM.ol) residue which
is formedby the rearrangement of theN-nitrosulfonamide residues
that generates a carbocation at C2, leading to a ring contraction and
hydrolysis of the adjacent glycosidic bond producing an anhydro-
mannose residue in the reducing end of the chain, which is further
stabilized by reduction with sodium borohydride (Lormeau, 1998).
Gammaparin, a LMWH produced by the physical depolymeriza-
tion of heparin in aqueous solution in the presence of isopropanol
by-irradiation (Bisio et al., 2001), has aquite similar 1HNMRspec-
trum to UFH; the main difference is the increase of signal intensity
at 3.56ppm arising from the H4 of the non-reducing N,6-sulfated
glucosamine residue (Bisio et al., 2001).
3.4. Monosaccharide composition of LMWHs
Throughout the depolymerization reaction new structures are
generated including extra features to the mono-dimensional NMR
spectra resulting in stronger signal overlap. For this reason, sig-
nals formonosaccharide compositionwere chosen from thosewith
minimal overlap in the HSQC spectra. Signals corresponding to
monosaccharides present in the UFH structure and those from
LMWHs were chosen as previously described (Guerrini et al., 2007;
Guerrini, Naggi, Guglieri, Santarsiero, & Torri, 2005) and are shown
in Fig. 4.
The monosaccharide composition for UFH and LMWH prepara-
tions is shown in Table 1. The major difference among the LMWHs
arise from monosaccharides unique to each depolymerization pro-
cess employed and the amount of glucuronic acid linked to ANS,3S
(G-ANS,3S), sequence which has only been detected in the pentasac-
charide motif active for AT (Guerrini et al., 2007).
3.5. 1H NMR features and monosaccharide composition of 5
enoxaparin copiesSince enoxaparin is the most widely used LMWH form, the
comparison among 5 different brands present within the same
market was conducted. As anticipated, the major signals on the
906 M.A. Lima et al. / Carbohydrate Polymers 85 (2011) 903–909
Fig. 4. HSQC spectra of different LMWHs. Signals used for monosaccharide composition are identiﬁed. LMWHs, low molecular weight heparins; ANS, 2-deoxy-2-sulfoamino-
d-glucopyranose; I2S, 2-O-sulfo-iduronic acid; G, glucuronic acid; A3S, 2-deoxy-3-O-sulfo-2-amino-d-glucopyranose; ANAc, 2-deoxy-2-acetylamino-d-glucopyranose; red,
terminal reducing residue with a conﬁguration; MNS, 2-deoxy-2-sulfamino-d-mannopyranose; 1,6-an.A, 2-amino-1,6-anhydro-2-deoxy--d-glucopyranose; 1,6-an.M, 2-
amino-1,6-anhydro-2-deoxy--d-mannopyranose; AM.ol, 2,5-anhydromannitol; U2S, 2-O-sulfo-4-deoxy--l-threo-hex-4-enopyranosil uronic acid; U, 4-deoxy--l-
threo-hex-4-enopyranosil uronic acid.
Table 1
Monosaccharide composition of LMWHs.
Agent Percentage (%) Degree of sulfation
ANS ANAc G-ANS,3S A6S ANSred MNS 1,6 an.A 1,6 an.M AM.ol G I I2S U U2S
Enoxaparin 75.00 5.50 4.50 90.64 9.00 0.75 2.25 3.00 0.00 14.45 4.62 62.43 0.58 17.92 2.60
Tinzaparin 77.32 5.67 6.96 87.88 10.05 0.00 0.00 0.00 0.00 10.98 4.88 71.95 0.00 12.20 2.66
Nadroparin 73.53 6.62 4.41 92.46 0.00 0.00 0.00 0.00 15.44 13.99 6.29 79.72 0.00 0.00 2.65
Gammaparin 86.46 6.63 6.92 87.24 0.00 0.00 0.00 0.00 0.00 16.48 6.59 76.92 0.00 0.00 2.57
ANS, 2-deoxy-2-sulfoamino-d-glucopyranose; I2S, 2-O-sulfo-iduronic acid; G, glucuronic acid; A3S, 2-deoxy-3-O-sulfo-2-amino-d-glucopyranose; ANAc, 2-deoxy-2-
acetylamino-d-glucopyranose;red, terminal reducing residuewithaconﬁguration;MNS, 2-deoxy-2-sulfamino-d-mannopyranose;1,6-an.A, 2-amino-1,6-anhydro-2-deoxy-
-d-glucopyranose; 1,6-an.M, 2-amino-1,6-anhydro-2-deoxy--d-mannopyranose; AM.ol, 2,5-anhydromannitol; U , 2-O-sulfo-4-deoxy--l-threo-hex-4-enopyranosil
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pronic acid; U, 4-deoxy--l-threo-hex-4-enopyranosil uronic acid.
H NMR spectra corresponded to the trisulfated disaccharide,
hich is the prevalent repeating unit present on UFH and LMWHs
Fig. 5).
The 1H spectra for all 5 enoxaparins are essentially the same,
uggesting that the samples are highly similar. Indeed, as shown
y the monosaccharide composition (Table 2), they are quite
omparable both in terms of monosaccharides unchanged by the
epolymerization reaction and those that arise from it. The similar
omposition of the ﬁve enoxaparins in Table 2 is reﬂected in their
imilar anti-factor Xa (100–110 IU) and anti-thrombin (25–30 IU)
er mg.2S
3.6. CD combined with multivariate analysis differentiates
LMWHs, UFH and other GAGs
NMR spectroscopy is, perhaps, the most advanced and accepted
technique for the differentiation of LMWHs and other complex
carbohydrates. However, owing its cost and limited availabil-
ity, this technique becomes unavailable to many laboratories.
Further analysis of the CD spectra performed by multivari-
ate analysis showed that this simple approach could be used
as a facile technique for the differentiation among the dif-
ferent classes of LMWHs and GAGs, as well as among the
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Table 2
Monosaccharide compostion of enoxaparin copies.
Agent Percentage (%) Degree of sulfation
ANS ANAc G-ANS,3S A6S ANSred MNS 1,6 an.A 1,6 an.M G I I2S U U2S
Enoxa1 74.26 4.95 3.71 90.05 10.40 1.49 1.49 3.71 13.45 3.51 63.16 1.17 18.71 2.61
Enoxa2 72.64 5.57 4.36 86.73 10.17 1.45 2.18 3.63 17.24 3.45 59.77 ∼1 18.97 2.54
Enoxa3 78.74 5.51 3.15 92.82 9.45 ∼1 ∼1 1.57 14.81 3.09 63.58 ∼1 17.90 2.66
Enoxa4 73.71 4.18 2.95 91.08 14.74 2.21 ∼1 1.47 12.83 4.28 65.78 ∼1 16.58 2.67
Enoxa5 75.00 5.50 4.50 90.64 9.00 ∼1 2.25 3.00 14.45 4.62 62.43 ∼1 17.92 2.60
Lovenox 76.34 4.58 4.58 92.55 8.4 2.29 1.53 2.29 12.23 4.32 61.15 ∼1 21.58 2.66
ANS, 2-deoxy-2-sulfoamino-d-glucopyranose; I2S, 2-O-sulfo-iduronic acid; G, glucuronic acid; A3S, 2-deoxy-3-O-sulfo-2-amino-d-glucopyranose; ANAc, 2-deoxy-2-
acetylamino-d-glucopyranose; red, terminal reducing residue with a conﬁguration;
2-deoxy--d-glucopyranose; 1,6-an.M, 2-amino-1,6-anhydro-2-deoxy--d-mannopyra
4-deoxy--l-threo-hex-4-enopyranosil uronic acid.
Fig. 5. 1H NMR of generic enoxaparins present on the same market. ANS, 2-deoxy-
2-sulfoamino-d-glucopyranose; I2S, 2-O-sulfo-iduronic acid; G, glucuronic acid;
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i3S, 2-deoxy-3-O-sulfo-2-amino-d-glucopyranose; ANAc, 2-deoxy-2-acetylamino-
-glucopyranose; 1,6-an.A, 2-amino-1,6-anhydro-2-deoxy--d-glucopyranose;
U2S, 2-O-sulfo-4-deoxy--l-threo-hex-4-enopyranosil uronic acid.
ame kind of heparin preparation from different manufactures
Fig. 6a–f).
The structural features that are introduced into LMWHs
hrough their unique depolymerization reaction used for their
roduction, as well as differences in the glycosidic linkage,
-acetylation, N- and O-sulfation patterns, monosaccharide com-
osition, different content of hexuronic and hexosamine residues
n heparins and naturally occurring GAGs resulted on unique
eatures in their respective CD spectra, which were readily dif-
erentiated by circular dichroism combined with multivariate
nalysis.
. Discussion
The LMWHs are now globally regarded as drug of choice for
ost-surgical prophylaxis of deep venous thrombosis (DVT) and,
ome of them, for the management of acute coronary syndromes.
ecently, these agents have also been approved for the treatment
f thrombotic disorders such as the cancer related thrombosis and
rterial ﬁbrillation.
They aredeﬁnedas salts of sulfatedGAGshaving an averageMW
f less than 8kDa and for which at least 60% of all molecules have
MW of less than 8kDa (Pharmacopoeia, 2008), and are produced
y fractionation of UFH or by its depolymerization. None of the cur-
ent LMWH products are prepared by fractionation, though early
orkused fractions rather thandepolymerized fragments (Johnson
t al., 1976). For this reason, dependingon thepatenteddepolymer-
zation procedure, different products are formed and each one ofMNS, 2-deoxy-2- sulfamino-d-mannopyranose; 1,6-an.A, 2-amino-1,6-anhydro-
nose; U2S, 2-O-sulfo-4-deoxy--l-threo-hex-4-enopyranosil uronic acid; U,
them has to be regarded as a distinct drug entity, since they exhibit
distinct chemical, pharmacological and biomedical proﬁles (Hirsh,
Warkentin, Raschke, Granger, Ohman, & Dalen, 1998).
With the development of various LMWHs, the introduction of
generic products in many countries, and the increasing trend to
substitute UFH, the need to investigatemore deeply the differences
among this highly complexkindof pharmacological agent is acquir-
ing importance (Hirsh et al., 1998; Hoppensteadt, Jeske, Fareed, &
Bermes, 1995).
Owing their complexity, the differentiation of several forms
of LMWHs was performed by spectroscopic and multivari-
ate approaches in order to better understand their different
chemical features that might explain their distinct biologi-
cal/pharmacological activities.
In fact, signiﬁcant differences were observed regarding their
monosaccharide composition, especially the amount of the
G-ANS,3S, sequence which has been only detected on the pentasac-
charide motif active for AT (Guerrini et al., 2007), besides the
differences arising from their unique production process.
The difference on the amount of G-ANS,3S directly reﬂects the
fact that the AT binding site can be modiﬁed by the depolymeriza-
tion reactions (Vismara et al., 2010), with a consequent decrease
of AT-mediated activity (Fareed, Hoppensteadt, Jeske, Clarizio, &
Walenga, 1997). In fact, while a mild nitrous acid treatment, pro-
duction of Nadroparin, preserve the structural integrity the AT
biding motif, strong reaction conditions can generate fragments
ending with a trisulfated anhydromannose residue (Casu et al.,
1981). Also, enzymatic treatment with heparinases I and II is able
to cleave theAT binding site leaving theAN,3,6S as reducing terminal
residue (Shriver et al., 2000; Yu et al., 2000). Thus, the reaction pro-
cedure used to produce LMWHs with different reactivity towards
least sterically hindered regions of the heparin chain can affect the
integrity of the AT biding motif (Shriver et al., 2000; Viskov, Just,
Laux,Mourier, & Lorenz, 2009; Vismara et al., 2010; Yu et al., 2000).
Differently, gammaparin is produced by a physical method
based on controlled gamma irradiation of heparin. A correlation
between the amount of irradiation towhich heparin is exposed and
the reduction of the fragment average size, as well as a good cor-
relation between USP potency and extent of irradiation, has been
observed (Bisio et al., 2001). Our data showed that the radiation
received by this given sample did not affect the integrity of its AT
biding motif which is crucial for a good USP potency.
Enoxaparinsare themost commonused formofLMWHs. For this
reason, a comparison among 5 enoxaparins from different man-
ufactures present within the same market was performed. Their
highly correlatedmonosaccharide composition leads to the conclu-
sion that the starting material used to produce the low molecular
mass form probably comes from similar or, perhaps, the same
source. Also, the highly similar monosaccharide composition of
those related to the depolymerization reaction suggests that differ-
ent producers used comparable manufacturing conditions. Again,
908 M.A. Lima et al. / Carbohydrate Polymers 85 (2011) 903–909
Fig. 6. Multivariate analysis of CD spectra from different LMWHs and naturally occurring GAGs. (a and d) Loading plot. (b and e) Cluster analysis of loading plot. (c and f)
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correlation matrix color map. U, unfracionated heparin; E, enoxaparins; T, tinzapar
hondroitin 6-sulfate; r, correlation coefﬁcient.
hese data reinforce the idea that the starting material and depoly-
erization conditions used for the production of LMWHs critically
eﬁne the ﬁnal product.
As stated before, the differentiation of LMWHs is quite impor-
ant, but the most advanced and accepted technique to this matter
s NMR, which is also a quite expensive and of limited accessibil-
ty technique. Recently, the combination of CD with PCA was used
or this matter (Rudd et al., 2009); however, the CD measurements
ere made on a purpose-built synchrotron CD beamline, which is
lso of limited access. In this present paper, we used a bench top CD
nstrument combinedwithmultivariate analysis and similar results
ere obtained, proving that simple and cheaper approaches can be
sed to differentiate this class of drugs.
Taken together, the data presented here explain some dif-
erences among LMWHs that could lead to their different
iological/pharmacological activities. However, further studies are
equired to better understand the correlation between the struc-
ure and biological properties of such drugs. Also, we showed that
ess expensive spectroscopic methods combined with multivari-
te approaches may be used as an additional analytical tool for the
ifferentiation of LMWHs and naturally occurring glycosaminogly-
ans.
As the copy versions of different branded LMWHs may be pro-
uced by different manufactures, it is important to characterize
hese agents by additional methods. The methods outlined in this
anuscript represent an approach that could be useful in assess-
ng the structural and chemical equivalence of thenewlydeveloped
opy versions of branded products.nadroparin; G, gammaparin; DS, dermatan sulfate; C4S, chondroitin 4-sulfate; C6S,
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